Covaxin demonstrates robust safety and immunogenicity in two-to-18 year old: Study
Bharat Biotech had conducted phase-II/III, open-label and multi-centre studies to evaluate the safety, reactogenicity and…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.